Apex Scientific

21+ access.
Research use only.

Before entering, confirm that you meet the age requirement and understand the research-use limitations that apply to every Apex product.

If provided, your email can be carried into checkout for convenience. It is not required to browse and does not subscribe you to marketing. Read the Privacy Notice, Research Use Policy, and Terms.

Leave site

Your acknowledgement is remembered on this device for 30 days.

Research use only Clear product information Free shipping on orders over $200 20% launch offer · Use code APEX101
Apex Scientific
SearchBag

Compound guide

TESAMORELIN

A pathway-focused guide to molecular mechanisms, published evidence, and the limits of interpretation.

Overview

A Summary:TESAMORELIN

Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH), a peptide signal involved in pituitary growth-hormone release.

It binds the GHRH receptor and can increase pulsatile growth-hormone signaling and downstream IGF-1 production, making the pathway useful for studying endocrine feedback and adipose-tissue biology.

An FDA-approved tesamorelin medicine exists for a specific indication and formulation. That approval does not extend to this research material, which is not represented as a medicine or substitute for an approved product.

Research model

Cellular & MolecularHow TESAMORELIN Is Studied

These receptors, enzymes, and signaling networks define the primary laboratory questions associated with this research material.

01Pituitary activation

GHRH receptor

At the cellular or molecular level

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells. This Gs-coupled receptor raises cyclic AMP, activates protein kinase A, and promotes pulsatile release of growth hormone.

02Liver + tissue response

Growth-hormone receptor

At the cellular or molecular level

Released growth hormone binds its receptor in the liver and other tissues, activating JAK2 and STAT signaling. The liver then increases production of insulin-like growth factor 1, or IGF-1.

03Visceral-fat biology

Adipose signaling

At the cellular or molecular level

Growth-hormone signaling changes how fat cells store and release lipids, including increased lipolytic signaling. Clinical research with the approved formulation focused on visceral abdominal fat in a specific disease-related setting.

Research interpretation

How to read the pathway.

01

Pituitary activation

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells.

02

Liver + tissue response

Released growth hormone binds its receptor in the liver and other tissues, activating JAK2 and STAT signaling.

03

Visceral-fat biology

Growth-hormone signaling changes how fat cells store and release lipids, including increased lipolytic signaling.

Evidence boundary

An FDA-approved tesamorelin medicine exists for a specific indication and formulation. That approval does not extend to this research material, which is not represented as a medicine or substitute for an approved product.

Read the evidence

Sources BehindThis Guide

FDA prescribing information and mechanism (opens in a new tab)Tesamorelin identity record (opens in a new tab)

One important note

Educational Notice

Controlled human findings come from a defined tesamorelin medicine studied in adults with HIV-associated lipodystrophy. Those results should be read within that formulation and population.

This guide summarizes molecular mechanisms, published evidence, and evidence limits in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.